MedPath

Adalimumab

These highlights do not include all the information needed to use ADALIMUMAB-ADAZ safely and effectively. See full prescribing information for ADALIMUMAB-ADAZ. ADALIMUMAB-ADAZ injection, for subcutaneous useInitial U.S. Approval: 2018This product is HYRIMOZ (adalimumab-adaz). HYRIMOZ (adalimumab-adaz) is biosimilar* to HUMIRA (adalimumab).

Approved
Approval ID

3468792f-63ef-4916-8ed1-8214f327d9dd

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 9, 2023

Manufacturers
FDA

Sandoz Inc.

DUNS: 005387188

FDA

Sandoz Inc

DUNS: 005387188

Products 4

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

adalimumab-adaz

PRODUCT DETAILS

NDC Product Code61314-391
Application NumberBLA761071
Marketing CategoryC73585
Route of AdministrationSUBCUTANEOUS
Effective DateNovember 21, 2024
Generic Nameadalimumab-adaz

INGREDIENTS (7)

ADALIMUMABActive
Quantity: 10 mg in 0.1 mL
Code: FYS6T7F842
Classification: ACTIB
ADIPIC ACIDInactive
Quantity: 0.22 mg in 0.1 mL
Code: 76A0JE0FKJ
Classification: IACT
MANNITOLInactive
Quantity: 4.2 mg in 0.1 mL
Code: 3OWL53L36A
Classification: IACT
POLYSORBATE 80Inactive
Quantity: 0.04 mg in 0.1 mL
Code: 6OZP39ZG8H
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

adalimumab-adaz

PRODUCT DETAILS

NDC Product Code61314-325
Application NumberBLA761071
Marketing CategoryC73585
Route of AdministrationSUBCUTANEOUS
Effective DateNovember 21, 2024
Generic Nameadalimumab-adaz

INGREDIENTS (7)

WATERInactive
Code: 059QF0KO0R
Classification: IACT
ADALIMUMABActive
Quantity: 80 mg in 0.8 mL
Code: FYS6T7F842
Classification: ACTIB
ADIPIC ACIDInactive
Quantity: 1.75 mg in 0.8 mL
Code: 76A0JE0FKJ
Classification: IACT
MANNITOLInactive
Quantity: 33.6 mg in 0.8 mL
Code: 3OWL53L36A
Classification: IACT
POLYSORBATE 80Inactive
Quantity: 0.32 mg in 0.8 mL
Code: 6OZP39ZG8H
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

adalimumab-adaz

PRODUCT DETAILS

NDC Product Code61314-332
Application NumberBLA761071
Marketing CategoryC73585
Route of AdministrationSUBCUTANEOUS
Effective DateNovember 21, 2024
Generic Nameadalimumab-adaz

INGREDIENTS (7)

ADALIMUMABActive
Quantity: 20 mg in 0.2 mL
Code: FYS6T7F842
Classification: ACTIB
ADIPIC ACIDInactive
Quantity: 0.44 mg in 0.2 mL
Code: 76A0JE0FKJ
Classification: IACT
MANNITOLInactive
Quantity: 8.4 mg in 0.2 mL
Code: 3OWL53L36A
Classification: IACT
POLYSORBATE 80Inactive
Quantity: 0.08 mg in 0.2 mL
Code: 6OZP39ZG8H
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

adalimumab-adaz

PRODUCT DETAILS

NDC Product Code61314-327
Application NumberBLA761071
Marketing CategoryC73585
Route of AdministrationSUBCUTANEOUS
Effective DateMarch 9, 2023
Generic Nameadalimumab-adaz

INGREDIENTS (7)

ADALIMUMABActive
Quantity: 40 mg in 0.4 mL
Code: FYS6T7F842
Classification: ACTIB
MANNITOLInactive
Quantity: 16.8 mg in 0.4 mL
Code: 3OWL53L36A
Classification: IACT
POLYSORBATE 80Inactive
Quantity: 0.16 mg in 0.4 mL
Code: 6OZP39ZG8H
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
ADIPIC ACIDInactive
Quantity: 0.88 mg in 0.4 mL
Code: 76A0JE0FKJ
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

Drug Labeling Information

INFORMATION FOR PATIENTS SECTION

LOINC: 34076-0Updated: 6/1/2024

17 PATIENT COUNSELING INFORMATION

Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Infections

Inform patients that Adalimumab-adaz may lower the ability of their immune system to fight infections. Instruct patients of the importance of contacting their doctor if they develop any symptoms of infection, including tuberculosis, invasive fungal infections, and reactivation of hepatitis B virus infections [see Warnings and Precautions (5.1, 5.2, 5.4)].

Malignancies

Counsel patients about the risk of malignancies while receiving Adalimumab- adaz [see Warnings and Precautions (5.2)].

Hypersensitivity Reactions

Advise patients to seek immediate medical attention if they experience any symptoms of severe hypersensitivity reactions.

Other Medical Conditions

Advise patients to report any signs of new or worsening medical conditions such as congestive heart failure, neurological disease, autoimmune disorders, or cytopenias. Advise patients to report any symptoms suggestive of a cytopenia such as bruising, bleeding, or persistent fever [see Warnings and Precautions (5.5, 5.6, 5.8, 5.9)].

Instructions on Injection Technique

Inform patients that the first injection is to be performed under the supervision of a qualified health care professional. If a patient or caregiver is to administer Adalimumab-adaz, instruct them in injection techniques and assess their ability to inject subcutaneously to ensure the proper administration of Adalimumab-adaz [see Instructions for Use].

For patients who will use the Adalimumab-adaz single-dose prefilled Sensoready Pen, tell them that they:

will hear**2 loud clicks**. The**1****st**** click** indicates that the injection has**started**. Several seconds later a**2****nd**** click** will indicate that the injection is almost**finished**.

must keep holding the Adalimumab-adaz single-dose prefilled Sensoready Pen firmly against their skin until they see a green indicator fill the window and stop moving.

Instruct patients to dispose of their used syringes or used Sensoready Pens in an FDA-cleared sharps disposal container immediately after use.Instruct patients not to dispose of syringes or pens in their household trash. Instruct patients that if they do not have an FDA-cleared sharps disposal container, they may use a household container that is made of a heavy-duty plastic, can be closed with a tight-fitting and puncture-resistant lid without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container.

Instruct patients that when their sharps disposal container is almost full, they will need to follow their community guidelines for the correct way to dispose of their sharps disposal container. Instruct patients that there may be state or local laws regarding disposal of used needles and syringes. Refer patients to the FDA’s website at http://www.fda.gov/safesharpsdisposal for more information about safe sharps disposal, and for specific information about sharps disposal in the state that they live in.

Instruct patients not to dispose of their used sharps disposal container in their household trash unless their community guidelines permit this. Instruct patients not to recycle their used sharps disposal container.

Manufactured by:

Sandoz Inc.

Princeton, NJ 08540

US License No. 2003

All third party trademarks are the property of their respective owners.

© Copyright 2025. All Rights Reserved by MedPath
Adalimumab - FDA Approval | MedPath